The Diabetes Cost Stack: Insulin Caps, CGM Coverage Rules, and the Supply Denials That Reverse

The type 1 threads we studied read like expense reports with rage in the margins: the insulin quote that collapsed 90% after one phone call (954 upvotes of "Worth the phone call!"), the Dexcom sensors rejected with a prior authorization on file, the annual ritual of re-proving a lifelong disease still exists. Diabetes is the most cost-engineered condition in America, which cuts both ways: the traps are everywhere, and so are the entitlements. Here's the whole stack.

Insulin: the $35 answer, by situation

• Medicare: covered insulin is capped at $35 for a month's supply, Part D deductible waived. Quoted more at the counter? The claim was processed wrong; ask the pharmacy to rerun it and the plan to correct it.
• Commercial insurance: each of the big three manufacturers runs a $35-a-month program (Lilly's Insulin Value Program, Novo's MyInsulinRx, Sanofi's Insulins Valyou), and manufacturer copay cards drop many brand insulins near zero on top of coverage.
• Uninsured: the same manufacturer programs mostly serve you too, plus Walmart's private-label insulins as a bridge (ask your prescriber whether the older formulations fit your regimen before switching anything).
• Pump users on Medicare, know the channel quirk: insulin used in a durable (Part B-covered) pump bills under Part B with its own $35 monthly coinsurance cap, separate from Part D. Pharmacies mis-channel this constantly; "this is Part B insulin for a covered pump" is the corrective sentence.

CGMs: the criteria are wider than your denial letter implies

Since the 2023 expansion, Medicare covers CGMs under Part B as durable medical equipment for anyone with diabetes treated with insulin, full stop (no minimum injections per day anymore), and for some non-insulin users with a documented history of problematic hypoglycemia. Part B pays 80% after the deductible; Medigap picks up the rest, which is part of why supplement math favors heavy DME users. The paperwork that makes it stick: a chart note from a visit within the last six months documenting the insulin treatment (or hypoglycemia history) and that you (or a caregiver) can use the device. On commercial plans, CGM coverage is near-universal for type 1 and increasingly standard for insulin-treated type 2, but it runs through prior authorization: the checklist is usually diagnosis, insulin regimen, and testing frequency, and a denial names which box the reviewer thinks is empty. Make the prescriber's office fill THAT box and resubmit.

The pattern with its own name: authorized, delivered, denied

The corpus post that distills it: Dexcom supplies rejected with the prior auth in hand. This is the approval-is-not-payment trap wearing a glucose sensor, and the counterplay is mechanical: call the plan with the authorization number and date range, state that the claim must be reprocessed against the existing authorization, get a reference number, and appeal with the auth letter attached if they refuse. Two diabetes-specific wrinkles: authorizations often specify a supplier or channel (pharmacy versus DME benefit), so a claim can die because it entered through the wrong door, and reauthorization windows lapse silently, so the fix for next time is calendaring the auth's end date a month early.

The supply treadmill, tuned

1. Know each item's channel: strips and lancets (pharmacy or Part B DME on Medicare), sensors and transmitters (DME or pharmacy by plan), pods and pump supplies (usually DME), insulin (Part D, or Part B if pump-administered). Wrong-channel claims deny with confusing codes that read like coverage refusals and are actually routing errors.
2. Refill on the first eligible day for anything with a shortage history or a shipping supplier (the same discipline as any scarce med).
3. Keep the usage documentation current: DME suppliers must verify continued use; a lapsed doctor's order or a missed "still using it" attestation stops shipments silently. When a shipment doesn't arrive, call the supplier first and ask what documentation they're waiting on.
4. Audit the [EOBs](/blog/how-to-read-an-eob) quarterly: diabetes generates enough claims that accumulator and coding errors hide easily, and deductible math decides whether December supply orders are free.
5. If costs still bite: manufacturer assistance programs cover pumps and CGMs too, state pharmaceutical assistance and Extra Help stack on Medicare, and diabetes-supply exchanges and clinics bridge gaps; the endocrinologist's office knows the local ones.